Alfentanil sublingual - Orexo

Drug Profile

Alfentanil sublingual - Orexo

Alternative Names: OX-51

Latest Information Update: 31 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orexo
  • Class Opioid analgesics
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Acute pain

Highest Development Phases

  • Phase II/III Acute pain

Most Recent Events

  • 29 Oct 2015 Alfentanil sublingual - Orexo is available for licensing worldwide as of 29 Oct 2015.
  • 31 Jul 2015 Alfentanil sublingual is still in phase-II/III development for Acute Pain (prevention) in Europe
  • 28 Aug 2013 Efficacy & adverse events data from a phase II/III trial in Acute pain (prevention) released by Orexo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top